Compare Stocks → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARAOTCMKTS:EMISNASDAQ:RTRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.72-5.3%$0.83$0.50▼$4.67$39.12M0.74593,657 shs194,571 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/ARTRXTravere Therapeutics$6.30-4.5%$26.56$8.98▼$24.96$321.63M0.67412,277 shs974,626 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+3.68%-1.57%-8.64%+34.34%-81.68%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%RTRXTravere Therapeutics-3.23%+10.00%-3.79%-20.48%-60.19%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.8329 of 5 stars3.41.00.04.21.81.71.3EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,262.49% UpsideEMISEmisphere TechnologiesN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CARA, RTRX, and EMIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.87N/AN/A$1.05 per share0.68EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/ARTRXTravere Therapeutics$175.34M1.83N/AN/A$5.15 per share1.22Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/13/2024 (Confirmed)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ARTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ALatest CARA, RTRX, and EMIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/ACARACara Therapeutics-$0.38N/A+$0.38N/AN/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43EMISEmisphere TechnologiesN/AN/AN/ARTRXTravere Therapeutics0.667.237.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%EMISEmisphere TechnologiesN/ARTRXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%EMISEmisphere Technologies72.90%RTRXTravere Therapeutics4.63%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.67 million52.37 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableCARA, RTRX, and EMIS HeadlinesSourceHeadlineAnalysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)markets.businessinsider.com - May 7 at 3:15 PMExpert Outlook: Travere Therapeutics Through The Eyes Of 6 Analystsmarkets.businessinsider.com - May 7 at 3:15 PMTravere: Q1 Earnings Snapshotstamfordadvocate.com - May 6 at 7:12 PMCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - April 17 at 4:04 PMTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyrealmoney.thestreet.com - February 23 at 3:07 PMTravere Therapeutics gains as EU backs kidney disease therapymsn.com - February 23 at 8:37 AMNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?msn.com - February 21 at 8:05 AMTravere Therapeutics price target raised by $4 at Citi, here's whyrealmoney.thestreet.com - February 17 at 7:51 AMTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competitionmarkets.businessinsider.com - February 16 at 10:57 AMEarnings Preview For Travere Therapeuticsbenzinga.com - February 14 at 4:00 PMTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospectsmarkets.businessinsider.com - January 11 at 7:54 AMOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganizationmarkets.businessinsider.com - December 7 at 5:53 PMTravere (TVTX) Up on Latest Portfolio Updates & Reorganizationmsn.com - December 6 at 5:04 PMBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganizationmarkets.businessinsider.com - December 5 at 8:07 PMTravere Therapeutics upgraded to Buy from Neutral at Citirealmoney.thestreet.com - December 5 at 2:51 PMTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatmentsmarketwatch.com - December 4 at 8:55 PMTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conferencebenzinga.com - November 21 at 6:25 PMPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - November 8 at 3:32 PMPreview: Travere Therapeutics's Earningsbenzinga.com - November 6 at 2:56 PMTravere Therapeutics Inc Ordinary Shares TVTXmorningstar.com - October 31 at 6:21 PMWedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendationmsn.com - September 30 at 10:26 AMWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Lowmsn.com - September 22 at 5:07 PMWhy Shares of Travere Therapeutics Are Slumping Thursdaymsn.com - September 21 at 3:15 PMBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challengesmarkets.businessinsider.com - September 21 at 3:15 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.